Bellecapital International Ltd. Sells 3,415 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Bellecapital International Ltd. lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 40.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,035 shares of the biopharmaceutical company’s stock after selling 3,415 shares during the period. Bellecapital International Ltd.’s holdings in Gilead Sciences were worth $564,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Newbridge Financial Services Group Inc. bought a new position in shares of Gilead Sciences during the 4th quarter valued at about $33,000. Annis Gardner Whiting Capital Advisors LLC lifted its position in shares of Gilead Sciences by 158.8% in the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 216 shares in the last quarter. Morton Brown Family Wealth LLC bought a new position in Gilead Sciences during the fourth quarter valued at approximately $35,000. Whipplewood Advisors LLC purchased a new position in Gilead Sciences during the 4th quarter valued at approximately $35,000. Finally, Synergy Investment Management LLC bought a new stake in Gilead Sciences in the 4th quarter worth approximately $40,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Down 0.7%

NASDAQ:GILD opened at $109.30 on Thursday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a 1-year low of $62.69 and a 1-year high of $119.96. The company has a 50-day moving average of $105.40 and a 200 day moving average of $101.91. The firm has a market cap of $135.96 billion, a PE ratio of 295.41, a price-to-earnings-growth ratio of 0.71 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.04. The company had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Gilead Sciences’s revenue was down .3% compared to the same quarter last year. During the same period last year, the company posted ($1.32) earnings per share. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.89%. The ex-dividend date is Friday, June 13th. Gilead Sciences’s payout ratio is currently 66.53%.

Insider Buying and Selling at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, May 30th. The shares were sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the completion of the transaction, the chief executive officer now owns 620,268 shares in the company, valued at $68,489,992.56. The trade was a 1.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total transaction of $266,000.00. Following the completion of the transaction, the chief financial officer now directly owns 168,174 shares in the company, valued at $17,893,713.60. This represents a 1.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 43,000 shares of company stock worth $4,630,310 over the last quarter. Insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on GILD shares. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $125.00 price objective for the company. DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a research report on Thursday, February 13th. BMO Capital Markets lifted their price target on Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada boosted their price objective on Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research note on Wednesday, February 12th. Nine equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $110.55.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.